Sangui Obtains CE Mark for Chitoskin Wound Pads

SanguiBioTech has been awarded the CE mark for its "Chitoskin" wound pads, authorizing the company to distribute and sell this medical product in the member countries of the European Union, effective immediately.

Sangui's Chitoskin product is expected to show significant advantages over existing technologies, as the natural polymer chitosan has outstanding properties playing an important role in wound healing. Because of its specific molecular structure, chitosan demonstrates in all phases of wound healing not only the desired physical characteristics but also most favorable biological effects, caused by the chemical similarity with the natural matrix.

Chitoskin is the first medical product for which Sangui has obtained an authorization.